drugset / Trial / NCT00567047

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

NCT00567047

Phase 1 Completed 96 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

Timeline

Start
2007-07
Primary completion
2009-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 50 mg